THE IN SILICO ONCOLOGY AND IN SILICO MEDICINE GROUP PARTICIPATES IN THE NEWLY ESTABLISHED CANCER RESEARCH CENTRE, CO-FOUNDED BY THE CYPRUS UNIVERSITY OF TECHNOLOGY AND THE GERMAN ONCOLOGY CENTRE
On 4th October 2018 the establishment of the Cancer Research Centre (CRC) co-founded by the Cyprus University of Technology (CUT) and the German Oncology Centre (GOC), was signed by CUT Rector Prof. Dr Andreas Anayiotos and GOC Director Prof. Dr Nikolaos Zamboglou in Limassol, Cyprus. The key speech at the founding ceremony was delivered by Prof. Emer. Michael Molls, Technical University of Munich.
The In Silico Oncology and In Silico Medicine Group (ISO&ISM_G), Institute of Communication and Computer Systems (ICCS), School of Electrical and Computer Engineering (SECE), National Technical University of Athens (NTUA) participates in CRC following an invitation. Before and after the founding ceremony, the 1st Cancer Research Centre Workshop took place where the Director of ISO&ISM_G Research Professor G. Stamatakos delivered a talk entitled "In Silico Oncology: Translating Oncosimulators to the Clinic." He put particular emphasis on the large scale EU-US research project CHIC on in silico oncology which was funded by the European Commission (EC) and coordinated by GS on behalf of ICCS, ECE, NTUA. It is noted that the CHIC project was rated as excellent and its outcomes were designated as "great achievements" by EC. The talk was very well received by the CRC consortium and his research suggestions were subsequently integrated into the CRC research priorities.
CRC focuses on tackling questions relating to cancer diagnosis, treatment, care and prevention, supported by world-class core scientific facilities. The aim of research collaboration is the practical application of high-quality basic research, forming a bridge between the cutting-edge science of the CUT, the state of the art GOC, cooperating international institutes, biotechnology companies and patient associations. CRC is a first-of-its kind hub in Cyprus for cancer research, which will expedite the discovery of new diagnostic tools and treatments through a collaborative “bench-to-bedside” approach.
The workshop offered an opportunity for knowledge transfer between science, clinic and enterprises that can spur innovation within the consortium and fellow stakeholders. The participants got a chance to meet, and network with key international players in the field of research oncology. The meeting enabled and drove dialogue and cooperation for research which led to the identification of common areas of interest for the future collaboration of the consortium with key European Institutes.
RELATED LINKS